Alan B. Sandler
Child and Adolescent Psychiatry
21545 Centre Pointe Pkwy
Santa Clarita, CA 91350
Santa Clarita, CA 91350
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 46 publications
C-reactive protein reduction post treatment is associated with improved survival in atezolizumab (anti-PD-L1) treated non-small cell lung cancer patients.
Journal: PloS one
Published: October 02, 2020
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.
Journal: The New England journal of medicine
Published: September 30, 2020
Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: March 12, 2020
Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR mutations.
Journal: Expert review of respiratory medicine
Published: December 13, 2019
Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook.
Journal: Cancer treatment reviews
Published: December 12, 2019
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.
Journal: The Lancet. Oncology
Published: October 25, 2018
Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1).
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: October 10, 2018
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.
Journal: The New England journal of medicine
Published: October 04, 2018
Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study.
Journal: European journal of cancer (Oxford, England : 1990)
Published: June 07, 2018
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.
Journal: The New England journal of medicine
Published: June 05, 2018
Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: May 29, 2018
Last Updated: 09/26/2026